Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences’ Scientific Advisory Board
Klotho Neurosciences (NASDAQ: KLTO) has appointed Dr. Merit Cudkowicz to its Scientific Advisory Board. Dr. Cudkowicz is the Chair of Neurology at Massachusetts General Hospital, Director of the Sean M. Healey & AMG Center for ALS, and Julieanne Dorn Professor of Neurology at Harvard Medical School. She is a member of the National Academy of Medicine and co-director of the Northeast ALS Consortium, overseeing 150+ clinical sites in the US and Canada.
The company, focused on developing cell and gene therapies for ALS, Alzheimer's, and Parkinson's disease, aims to leverage Dr. Cudkowicz's expertise in clinical trial design and execution. Their approach centers on a patent-protected product candidate expressing the Klotho gene transcribed protein called 's-KL' or 'secreted Klotho' for ALS treatment.
Klotho Neurosciences (NASDAQ: KLTO) ha nominato la Dott.ssa Merit Cudkowicz nel suo Consiglio Consultivo Scientifico. La Dott.ssa Cudkowicz è la Presidente della Neurologia presso il Massachusetts General Hospital, Direttrice del Sean M. Healey & AMG Center for ALS e Professoressa di Neurologia alla Harvard Medical School. È membro della National Academy of Medicine e co-direttrice del Northeast ALS Consortium, supervisando oltre 150 siti clinici negli Stati Uniti e in Canada.
L'azienda, focalizzata nello sviluppo di terapie cellulari e geniche per la SLA, l'Alzheimer e il Parkinson, mira a sfruttare l'expertise della Dott.ssa Cudkowicz nella progettazione e nell'esecuzione di studi clinici. Il loro approccio si concentra su un candidato prodotto protetto da brevetto che esprime la proteina trascritta del gene Klotho chiamata 's-KL' o 'Klotho secreto' per il trattamento della SLA.
Klotho Neurosciences (NASDAQ: KLTO) ha nombrado a la Dra. Merit Cudkowicz en su Consejo Asesor Científico. La Dra. Cudkowicz es la presidenta de neurología en el Hospital General de Massachusetts, directora del Centro Sean M. Healey & AMG para la ELA, y profesora de neurología en la Facultad de Medicina de Harvard. Es miembro de la Academia Nacional de Medicina y co-directora del Consorcio del Noreste de ELA, supervisando más de 150 sitios clínicos en EE. UU. y Canadá.
La empresa, centrada en el desarrollo de terapias celulares y génicas para la ELA, el Alzheimer y el Parkinson, tiene como objetivo aprovechar la experiencia de la Dra. Cudkowicz en el diseño y la ejecución de ensayos clínicos. Su enfoque se centra en un candidato a producto protegido por patente que expresa la proteína transcrita del gen Klotho, llamada 's-KL' o 'Klotho secretado' para el tratamiento de la ELA.
Klotho Neurosciences (NASDAQ: KLTO)는 Merit Cudkowicz 박사를 과학 자문 위원회에 임명했습니다. Cudkowicz 박사는 매사추세츠 종합병원에서 신경학과 의장직을 맡고 있으며, Sean M. Healey & AMG ALS 센터의 책임자이자 하버드 의대 신경학 교수입니다. 그녀는 미국 및 캐나다의 150개 이상의 임상 사이트를 감독하는 북동부 ALS 컨소시엄의 공동 디렉터이자 국가 의학 아카데미의 회원입니다.
이 회사는 ALS, 알츠하이머, 파킨슨병을 위한 세포 및 유전자 치료법 개발에 중점을 두고 있으며, Cudkowicz 박사의 임상 시험 설계 및 실행에 대한 전문성을 활용하는 것을 목표로 하고 있습니다. 그들의 접근 방식은 's-KL' 또는 '분비형 Klotho'라고 불리는 Klotho 유전자로부터 전사된 단백질을 발현하는 특허 보호 제품 후보에 중심을 두고 있습니다.
Klotho Neurosciences (NASDAQ: KLTO) a nommé le Dr Merit Cudkowicz à son Conseil Consultatif Scientifique. Le Dr Cudkowicz est le président du département de neurologie au Massachusetts General Hospital, directeur du Sean M. Healey & AMG Center for ALS et professeur de neurologie à l'École de Médecine de Harvard. Elle est membre de l'Académie nationale de médecine et co-directrice du Consortium du Nord-Est sur l'ALS, supervisant plus de 150 sites cliniques aux États-Unis et au Canada.
L'entreprise, axée sur le développement de thérapies cellulaires et géniques pour la SLA, la maladie d'Alzheimer et la maladie de Parkinson, vise à tirer parti de l'expertise du Dr Cudkowicz dans la conception et l'exécution des essais cliniques. Leur approche se concentre sur un candidat produit protégé par un brevet exprimant la protéine transcrite du gène Klotho appelée 's-KL' ou 'Klotho sécrété' pour le traitement de la SLA.
Klotho Neurosciences (NASDAQ: KLTO) hat Dr. Merit Cudkowicz in seinen Wissenschaftlichen Beirat berufen. Dr. Cudkowicz ist die Vorsitzende für Neurologie am Massachusetts General Hospital, Direktorin des Sean M. Healey & AMG Center for ALS und Professorin für Neurologie an der Harvard Medical School. Sie ist Mitglied der National Academy of Medicine und Co-Direktorin des Northeast ALS Consortium, das über 150 klinische Standorte in den USA und Kanada überwacht.
Das Unternehmen, das sich auf die Entwicklung von Zell- und Gentherapien für ALS, Alzheimer und Parkinson konzentriert, zielt darauf ab, Dr. Cudkowicz' Expertise in der Planung und Durchführung von klinischen Studien zu nutzen. Ihr Ansatz basiert auf einem patentgeschützten Produktkandidaten, der das transkribierte Protein des Klotho-Gens exprimiert, das als 's-KL' oder 'sekretierte Klotho' für die ALS-Behandlung bekannt ist.
- Appointment of renowned ALS expert Dr. Merit Cudkowicz strengthens scientific leadership
- Access to Northeast ALS Consortium network of 150+ clinical sites for potential trials
- Company has patent protection for their s-KL product candidate
- None.
Klotho Neurosciences, Inc. continues to strengthen its advisory teams with recent new additions of Neuroscience and Big Pharma leaders to Scientific Advisory Board and Board of Directors
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer’s and Parkinson’s disease is proud to announce the appointment of Dr. Merit Cudkowicz, MD, MSc, to its Scientific Advisory Board (SAB).
Dr. Cudkowicz is the Chair of Neurology at MGH, Director of the Sean M. Healey & AMG Center for ALS, and is the Julieanne Dorn Professor of Neurology at Harvard Medical School. A member of the National Academy of Medicine, Dr. Cudkowicz has been a leading clinician in promoting and devising more efficient methods for the development of therapies for people with neurological disorders such as ALS. She is one of the founders and co-directors of the Northeast ALS (NEALS) Consortium, a group of over 150 clinical sites in the United States and Canada dedicated to performing collaborative, academic-led clinical trials in ALS subjects.
In welcoming Dr. Cudkowicz to the SAB, Dr. Joseph Sinkule, the Founder, CEO, and Chairman of Klotho Neurosciences commented: “Dr. Cudkowicz is clearly a world-renowned clinician and authority in the field of ALS, which is also often referred to as Lou Gehrig's disease. We are honored to have her join our SAB and help guide us in clinical trial design and execution. We firmly believe that the Company’s gene therapy approach could be an important advance in the treatment of ALS using our patent-protected product candidate expressing the Klotho gene transcribed protein called ‘s-KL’ or “secreted Klotho.”
In responding, Dr. Cudkowicz expressed her appreciation for the invitation to join the SAB, stating that “It is vitally important that a company like Klotho Neurosciences receives the full support and guidance from members of their SAB to maximize the opportunity to expeditiously develop a safe and effective new treatment for ALS based on the Company’s proprietary s-KL. There is a clear and absolute urgent need for new and effective treatments for this devastating, universally-fatal disease, and I hope to be able to assist Klotho Neurosciences along the path to success.”
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biopharmaceutical company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the “anti-aging” human Klotho gene and it’s novel delivery system (s-KL/AAV.myo) to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The company’s current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostics. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
For more information, contact:
Eric Boyd
Investor Relations
Email: IR@klothoneuro.com
Website: www.klothoneuro.com
Forward-Looking Statements:
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
FAQ
Who is the latest addition to Klotho Neurosciences (KLTO) Scientific Advisory Board?
What is Klotho Neurosciences' (KLTO) main product candidate for ALS treatment?
What diseases is Klotho Neurosciences (KLTO) targeting with their therapies?
